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Background: The clinical benefits of postoperative radiation therapy (PORT) for patients with thymoma are
still controversial. In the absence of defined guidelines, prognostic factors such as stage, status of surgical
margins, and histology are often considered to guide the choice of adjuvant treatment (radiotherapy and/or
chemotherapy). In this study, we describe our single-institution experience of three-dimensional conformal
PORT administered as adjuvant treatment to patients with thymoma.
Methods: Twenty-two consecutive thymoma patients (eleven male and eleven female) with a median age of
52 years and treated at our institution by PORT were analyzed. The patients were considered at high risk of
recurrence, having at least one of the following features: stage IIB or III, involved resection margins, or
thymic carcinoma histology. Three-dimensional conformal PORT with a median total dose on clinical target
volume of 50 (range 44–60) Gy was delivered to the tumor bed by 6–20 MV X-ray of the linear accelerator.
Follow-up after radiotherapy was done by computed tomography scan every 6 months for 2 years and yearly
thereafter.
Results: Two of the 22 patients developed local recurrence and four developed distant metastases. Median
overall survival was 100 months, and the 3-year and 5-year survival rates were 83% and 74%, respectively.
Median disease-free survival was 90 months, and the 5-year recurrence rate was 32%. On univariate
analysis, pathologic stage III and presence of positive surgical margins had a significant impact on patient
prognosis. Radiation toxicity was mild in most patients and no severe toxicity was registered.
Conclusion: Adjuvant radiotherapy achieved good local control and showed an acceptable toxicity profile in
patients with high-risk thymoma.
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Introduction
Thymomas are neoplasms originating from the thymic gland and are the most frequent primary mediastinal
malignancies. Based on their pathologic features, thymomas can be divided into several categories with a
different prognosis. Thymic carcinoma and type B3 thymoma, for example, have a poorer prognosis than the
type A, AB, B1, and B2 histotypes, according to the World Health Organization classification. However, the
best prognostic classification for thymomas is Masaoka staging, according to which stage III and IV disease
are characterized by significantly worse outcome and rate of recurrence compared with stage I and II.1–3
Surgical resection is the mainstay of treatment for localized disease, and is often followed by adjuvant
radiotherapy. Specifically, radiotherapy is recommended in the event of incomplete excision and/or advanced
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disease (stage III or IV, according to Masaoka), whereas stage II thymoma, except for thymic carcinoma,
does not have a clear indication for adjuvant radiotherapy. Historically, the recurrence rate varies from 0% to
30% in stage II thymoma, and in stage III ranges from 13% to 64%.4 Stage IV thymomas are often
unresectable, and chemotherapy is considered to be the best therapeutic option, although in selected cases
debulking surgery followed by adjuvant chemoradiation can represent a valid alternative.4 In the presence of
an indication for adjuvant radiotherapy, a dose ranging from 45 to 50 Gy is strongly recommended for totally
resected lesions (R0 resection), whereas 54 Gy should be administered in the presence of microscopically
positive resection margins (R1 resection). In the event of macroscopic residual disease (R2 resection), a total
dose of 60 Gy is recommended.4,5 External beam radiotherapy should be performed using the three-
dimensional conformal technique, or intensity-modulated radiation therapy. Due to the very low frequency of
lymph node metastases, the treatment plan should cover only the primary site of disease, and include nodal
irradiation only in the presence of clinically evident lymph node involvement. In addition to radiotherapy,
adjuvant chemotherapy can be considered as a treatment option in the presence of adverse features, such as
incomplete resection and/or a pathologic diagnosis of thymic carcinoma.1 Nevertheless, to date, the role of
adjuvant chemotherapy in the treatment of thymoma remains unclear.
Patients and methods
Patients
Twenty-two consecutive patients with a histologic diagnosis of thymoma or thymic carcinoma and treated at
our institution (National Tumour Institute of Naples, Foundation G Pascale) with surgery followed by adjuvant
radiotherapy were included in this retrospective study. Eleven of the 22 patients (50%) were male. The
median age was 52 (range 32–72) years. Myasthenia was present at diagnosis in four patients (18%) and
developed later during treatment in one further patient. The most frequent pathologic type was B2 thymoma,
accounting for nine cases (41%), while five patients (22%) had AB type and three patients had thymic
carcinoma. Eleven of the 22 patients had stage III disease and the remaining eleven had stage II disease
according to the Masaoka classification. R0 resection was achieved in 14 patients (64%), but only R1
resection was achieved in the remaining eight patients (36%). All patients had at least one of the following
risk factors: stage III disease, stage IIb (macroscopic extracapsular involvement), thymic carcinoma, or
positive resection margins (R1 surgery). External beam radiotherapy was administered using 6–20 MV X-ray
of the linear accelerator. The patients underwent computed tomography (CT) and a three-dimensional
treatment plan simulation. In all patients, the clinical target volume encompassed the entire mediastinal
space in which the tumor was located. Elective nodal irradiation was not performed. The planning target
volume was calculated by adding a margin to the clinical target volume that ranged from 0.5 to 1 cm. The
total dose delivered varied from a minimum of 44 Gy to a maximum of 60 Gy, according to stage and margin
status. The dose fraction was either 2.0 or 1.8 Gy per day. In addition to radiotherapy, adjuvant
chemotherapy was administered for three stage III patients (13%); in all three cases, a polychemotherapy
regimen containing cyclophosphamide, cisplatin, and doxorubicin was administered prior to radiation therapy.
The patient and treatment characteristics are described in detail in Table 1.
Table 1 Patients and treatment characteristics
Follow-up
A CT scan was performed before and after surgery, and 30–45 days after completion of adjuvant
radiotherapy. In addition, follow-up was performed with periodic clinical visits consisting of anamnesis,
physical examination, and a CT scan. Follow-up visits were at 6-monthly intervals during the first 2 years
following the end of radiotherapy. After 2 years, follow-up was yearly.
Disease-free survival was calculated starting from the end of radiotherapy through to recurrence or death.
Overall survival was considered as the time elapsing from the end of radiotherapy to patient death. In the
absence of either recurrence or death, patients were censored to the date of the last follow-up visit. Acute
toxicity was determined by analyzing the side effects occurring within 3 months from the beginning of
radiotherapy. Late toxicity was determined by evaluating the side effects occurring after 3 months from the
beginning of radiotherapy.
Statistical analysis
Actuarial overall survival and disease-free survival were estimated at 3 and 5 years using the Kaplan–Meier
method. Univariate analysis and the log-rank test were used to investigate the influence of the demographic
and clinical variables on relapse rate and survival. All statistical tests were two-sided and a P-value of 0.05
was considered to be statistically significant.
Results
Twenty-two patients were treated from March 2003 to March 2013. Median overall survival was 100 months,
while the 3-year and 5-year overall survival rates were 83% and 74%, respectively. Median disease-free
survival was 90 months, while the 3-year and 5-year relapse rates were 16% and 32%, respectively (Figure
1). On univariate analysis, only stage and margin status had a significant impact on the outcome. With
regard to stage, the median overall survival was 100 months for stage IIA/IIB patients and 60 months for
stage III patients (P=0.032). In addition, disease-free survival was 90 months for stage IIA/IIB versus 48
months for stage III patients (P=0.035). With regard to margin status, the median overall survival and
disease-free survival for the R0 subgroup versus the R1 subgroup were 100 months versus 36 months
(P=0.009) and 90 months versus 32 months (P=0.029), respectively. Age did not have any effect on
prognosis. Survival and relapse rates in relation to all the aforementioned variables are shown in Table 2.
Seven patients experienced disease relapse, two of which were locoregional and five were distant
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recurrences. Two patients had their radiotherapy interrupted at 44 Gy because of the occurrence of grade 3
dysphagia, which was the most frequent acute toxicity, and was observed in a total of eight patients (40%),
four being grade 2 and two being grade 1. All the patients recovered from dysphagia during treatment or
within a maximum of 2 weeks after the end of radiotherapy, and no chronic swallowing dysfunction was
observed. Dyspnea was reported in three patients, accompanied by chest pain in two cases. In all three
patients, the symptoms resolved on antibiotic and symptomatic therapy. A list of the acute side effects
observed in this study is provided in Table 3.
Figure 1 Kaplan–Meier curves for overall survival.
Table 2 Univariate analysis
Abbreviations: OS, overall survival; NS, not statistically significant; RR, relapse
rate.
Table 3 Acute toxicity reported as percentages
Note: *Only for chemotherapy-treated patients.
Abbreviation: G, grade of toxicity.
Discussion
To date, the role of adjuvant radiotherapy in the treatment of thymoma has not been clearly defined. Several
controversial clinical studies have investigated the effect of adjuvant radiotherapy in patients at high risk of
recurrence due to either locally advanced stage or presence of positive margins after surgery.5–10 Ruffini et al
highlighted the inconsistency of the results of these studies, showing both negative and positive results of
radiotherapy in prolonging survival in totally resected stage III thymomas.10,11 Much less controversial is the
role of radiotherapy in completely resected stage II disease, where increasing evidence suggests an absence
of additional benefit provided by adjuvant radiotherapy.11–13 Nevertheless, some authors have underscored
the importance of certain “risk factors”, such as pleural invasion, margin status, and pathology in the
indication of adjuvant radiotherapy for stage II thymoma.13,14 According to these authors, thymic carcinoma
indeed represents a different disease and, consequently, it is advisable to manage it differently from other
thymomas. The US and European guidelines recommend use of adjuvant radiotherapy in thymic carcinoma,
starting from stage II disease.1 Our report entails use of adjuvant radiotherapy in patients with at least one
of the following risk factors: stage IIb (macroscopic extracapsular extension), stage III, not totally
microscopically resected thymoma (R1 resection), and thymic carcinoma (starting from stage II). We
observed a remarkable median overall survival of 100 months and 3-year and 5-year actuarial survival rates
of 83% and 74%, respectively. These data are particularly impressive if we consider that 35% of our patients
had not undergone radical surgery (R1 resection). At univariate analysis, the margin status (R0 versus R1)
and pathologic staging had a significant impact on prognosis, with the patients undergoing R1 resection and
those having stage III disease being at higher risk of developing recurrence. Five of the eight R1 patients
relapsed within 5 years; three of these patients had distant relapses (two lung and one bone) and two had
local recurrences (pleural metastases). These results are completely in line with previously published data.15
On the other hand, histology did not affect the prognosis, although this finding may be due to the small
sample size. Moreover, four of six recurrences were distant, highlighting the fairly good local control reached
by adjuvant radiotherapy. Treatment-related toxicity was generally mild, with grade 2 dysphagia being the
worse side effect encountered. Neutropenia occurred only in CT-treated patients and did not affect
subsequent administration of radiotherapy. Late toxicity was not observed. Of note, in previously published
clinical trials, grade 1 and 2 pneumonitis were reported, especially when a large clinical target volume was
encompassed,16 but we did not observe this side effect in our study. Moreover, we did not find cardiovascular
toxicity (pericarditis and pericardial effusion), which is sometimes described in the literature,17 although this
could be due to the relatively short follow-up period (10 years) and the small number of patients examined.
Conclusion
We can conclude that adjuvant radiotherapy, using a three-dimensional conformal technique and
administering a total dose ranging from 45 to 60 Gy, has the potential to be well tolerated and to achieve
good disease control in patients with a diagnosis of thymoma at high risk of recurrence.
The main limitations of our study are the small sample size and the lack of a control arm treated by
conventional surgery alone with or without adjuvant intensity-modulated radiation therapy or
chemoradiation. Therefore, any potential conclusions regarding the efficacy and safety of this treatment need
to be confirmed in larger randomized trials.
Disclosure
10/11/16 18:58[Full text] Adjuvant treatment in patients at high risk of recurrence of thymoma: | OTT
Page 4 of 6https://www.dovepress.com/adjuvant-treatment-in-patients-at-high-risk-of-recurrence-of-thymoma-e-peer-reviewed-fulltext-article-OTT
The authors report no conflicts of interest in this work.
References
1. National Comprehensive Cancer Network. NCCN clinical practice guidelines in oncology (NCCN guidelines
version I. 2014). Available from: http://www.nccn.org/professionals/physician_gls/f_guidelines.asp.
Accessed February 20, 2015.
2. Eng TY, Fuller CD, Jagirdar J, Bains Y, Thomas CR Jr. Thymic carcinoma: state of the art review. Int J
Radiat Oncol Biol Phys. 2004;59(3):654–664.
3. Koppitz H, Rockstroh JK, Schüller H, et al. State-of-the-art classification and multimodality treatment of
malignant thymoma. Cancer Treat Rev. 2012;38(5):540–548.
4. Kondo K. Optimal therapy for thymoma. J Med Invest. 2008;55(1–2):17–28.
5. Gomez D, Komaki R, Yu J, Ikushima H, Bezjak A. Radiation therapy definitions and reporting guidelines for
thymic malignancies. J Thorac Oncol. 2011;6(7 Suppl 3):S1743–S1748.
6. Kondo K. Optimal therapy for thymoma. J Med Invest. 2008;55(1–2):17–28.
7. Utsumi T, Shiono H, Kadota Y, et al. Postoperative radiation therapy after complete resection of thymoma
has little impact on survival. Cancer. 2009;115(23):5413–5420.
8. Korst RJ, Kansler AL, Christos PJ, Mandal S. Adjuvant radiotherapy for thymic epithelial tumors: a
systematic review and meta-analysis. Ann Thorac Surg. 2009;87(5):1641–1647.
9. Eng TY, Thomas CR Jr. Radiation therapy in the management of thymic tumors. Semin Thorac Cardiovasc
Surg. 2005;17(1):32–40.
10.Quintanilla-Martinez L, Wilkins EW Jr, Choi N, Efird J, Hug E, Harris NL. Thymoma. Histologic
subclassification is an independent prognostic factor. Cancer. 1994;74(2):606–617.
11.Ruffini E, Mancuso M, Oliaro A, et al. Recurrence of thymoma: analysis of clinicopathologic features,
treatment, and outcome. J Thorac Cardiovasc Surg. 1997;113(1):55–63.
12.Rena O, Papalia E, Oliaro A, et al. Does adjuvant radiation therapy improve disease-free survival in
completely resected Masaoka stage II thymoma? Eur J Cardiothorac Surg. 2007;31(1):109–113.
13.Mangi AA, Wright CD, Allan JS, et al. Adjuvant radiation therapy for stage II thymoma. Ann Thorac Surg.
2002;74(4):1033–1037.
14.Haniuda M, Morimoto M, Nishimura H, Kobayashi O, Yamanda T, Iida F. Adjuvant radiotherapy after
complete resection of thymoma. Ann Thorac Surg. 1992;54(2):311–315.
15.Yan J1, Liu Q, Moseley JN, et al. Adjuvant radiotherapy for stages II and III resected thymoma: a single-
institutional experience. Am J Clin Oncol. In press 2014.
16.Sugie C, Shibamoto Y, Ikeya-Hashizume C, et al. Invasive thymoma: postoperative mediastinal
irradiation, and low-dose entire hemithorax irradiation in patients with pleural dissemination. J Thorac
Oncol. 2008;3(1):75–81.
17.Komaki R, Gomez DR. Radiotherapy for thymic carcinoma: adjuvant, inductive, and definitive. Front
Oncol. 2014;3:330.
 This work is published and licensed by Dove Medical Press Limited. The full terms of this
license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons
Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms.
Non-commercial uses of the work are permitted without any further permission from Dove Medical Press
Limited, provided the work is properly attributed. For permission for commercial use of this work, please see




Oral vinorelbine: a feasible and safe partner for radiotherapy in the
treatment of locally advanced non-small cell lung cancer
Perri F, Lazzari G, Della Vittoria Scarpati G, Silvano G
Other article by this author:
10/11/16 18:58[Full text] Adjuvant treatment in patients at high risk of recurrence of thymoma: | OTT
Page 5 of 6https://www.dovepress.com/adjuvant-treatment-in-patients-at-high-risk-of-recurrence-of-thymoma-e-peer-reviewed-fulltext-article-OTT
OncoTargets and Therapy 2016, 9:2359-2364
Published Date: 19 April 2016
REVIEW HIGHLY ACCESSED
Causative factors for formation of toxic islet amyloid polypeptide
oligomer in type 2 diabetes mellitus
Jeong HR, An SSA
Clinical Interventions in Aging 2015, 10:1873-1879
Published Date: 19 November 2015
ORIGINAL RESEARCH HIGHLY ACCESSED
Increased serum levels of interleukin-10 predict poor prognosis in
extranodal natural killer/T-cell lymphoma patients receiving
asparaginase-based chemotherapy
Wang H, Wang L, Wuxiao ZJ, Huang HQ, Jiang WQ, Li ZM, Lu Y, Xia ZJ
OncoTargets and Therapy 2015, 8:2589-2599
Published Date: 14 September 2015
REVIEW HIGHLY ACCESSED
Mutations in presenilin 2 and its implications in Alzheimer’s disease and
other dementia-associated disorders
Cai Y, An SSA, Kim SY
Clinical Interventions in Aging 2015, 10:1163-1172
Published Date: 14 July 2015
REVIEW HIGHLY ACCESSED
A new recombinant factor VIII: from genetics to clinical use
Santagostino E
Drug Design, Development and Therapy 2014, 8:2507-2515
Published Date: 12 December 2014
ORIGINAL RESEARCH HIGHLY ACCESSED
Green synthesis of water-soluble nontoxic polymeric nanocomposites
containing silver nanoparticles
Prozorova GF, Pozdnyakov AS, Kuznetsova NP, Korzhova SA, Emel’yanov AI, Ermakova TG,
Fadeeva TV, Sosedova LM
International Journal of Nanomedicine 2014, 9:1883-1889
Readers of this article also read:
10/11/16 18:58[Full text] Adjuvant treatment in patients at high risk of recurrence of thymoma: | OTT
Page 6 of 6https://www.dovepress.com/adjuvant-treatment-in-patients-at-high-risk-of-recurrence-of-thymoma-e-peer-reviewed-fulltext-article-OTT
Published Date: 16 April 2014
ORIGINAL RESEARCH HIGHLY ACCESSED
Methacrylic-based nanogels for the pH-sensitive delivery of 5-
Fluorouracil in the colon
Ashwanikumar N, Kumar NA, Nair SA, Kumar GS
International Journal of Nanomedicine 2012, 7:5769-5779
Published Date: 15 November 2012
ORIGINAL RESEARCH HIGHLY ACCESSED
Cross-linked acrylic hydrogel for the controlled delivery of hydrophobic
drugs in cancer therapy
Deepa G, Thulasidasan AK, Anto RJ, Pillai JJ, Kumar GS
International Journal of Nanomedicine 2012, 7:4077-4088
Published Date: 27 July 2012
ORIGINAL RESEARCH HIGHLY ACCESSED
Particle size reduction to the nanometer range: a promising approach to
improve buccal absorption of poorly water-soluble drugs
Rao S, Song Y, Peddie F, Evans AM
International Journal of Nanomedicine 2011, 6:1245-1251
Published Date: 20 June 2011
CASE REPORT HIGHLY ACCESSED
Crystallization after intravitreal ganciclovir injection
Pitipol Choopong, Nattaporn Tesavibul, Nattawut Rodanant
Clinical Ophthalmology 2010, 4:709-711
Published Date: 14 July 2010
ORIGINAL RESEARCH HIGHLY ACCESSED
Characterization of complexation of poly (N-isopropylacrylamide-co-2-
(dimethylamino) ethyl methacrylate) thermoresponsive cationic
nanogels with salmon sperm DNA
Jim Moselhy, Tasnim Vira, Fei-Fei Liu, et al
International Journal of Nanomedicine 2009, 4:153-164
Published Date: 24 August 2009
